Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acambis begins phase II smallpox vaccine trial
MVA vaccines are a weakened form of smallpox vaccine. MVA3000 is being developed for use in people for whom the traditional smallpox vaccine is not recommended, such as
MVA vaccines are a weakened form of smallpox vaccine. MVA3000 is being developed for use in people for whom the traditional smallpox vaccine is not recommended, such as
Patients with a diagnosis of stage three or four malignant melanoma who have not been previously treated with chemotherapy for their metastatic disease are being recruited. Melanoma is
The company expects to file an investigational new drug application (IND) in late 2005 or early 2006, followed by a biologic license application in the second half of
The objectives of the study are to determine the maximum tolerated dose, and to evaluate the safety and pharmacokinetics of the drug. Up to 40 patients will be
The FDA intervened in 2003 to stop trials of Varisolve amid fears that the treatment could increase the risk of embolism in patients. In March 2005, Provensis submitted
The report gives twelve observations that raise concerns about the quality control and reporting procedures within Able. Most pertinently the report claims “the quality unit and senior management
As part of the $300 million takeover, shareholders will receive $4.40 in cash for each share of common stock, $517.65 in cash for each share of Series A
“This collaboration represents yet another important disease biomarker discovery program for Caprion,” noted Dr Daniel Chelsky, chief scientific officer of Caprion Pharmaceuticals. “This study reflects how Caprion’s biomarker
Operating revenues for the second quarter of 2005 of $1.53 billion represent a 35% increase on revenues of $1.12 billion for the same period in 2004. This has
The FDA is keen to encourage the development of other flu vaccines after suffering from supply shortages last year as a result of manufacturing problems at a Chiron